• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man.

作者信息

Battaglia R, Strolin Benedetti M, Mantegani S, Castelli M G, Cocchiara G, Dostert P

机构信息

Farmitalia Carlo Erba, Research and Development-Erbamont Group, Milan, Italy.

出版信息

Xenobiotica. 1993 Dec;23(12):1377-89. doi: 10.3109/00498259309059447.

DOI:10.3109/00498259309059447
PMID:7907829
Abstract
  1. The disposition and urinary metabolic pattern of 14C-cabergoline was studied in rat, monkey and man after oral administration of the labelled drug. 2. In all species radioactivity was mainly excreted in faeces, with urinary excretion accounting for 11, 13 and 22% of the dose in rat, monkey and man, respectively. 3. After oral treatment, biliary excretion of radioactivity in rat accounted for 19% of the dose within 24 h. 4. Unchanged drug in 0-24-h urine samples of rat, monkey and man amounted to 20, 9 and 10% of urinary radioactivity, respectively. In the 24-72-h urine samples of all species the relative percentage of unchanged drug increased compared with that measured in the 0-24-h urine. 5. The main metabolite was the acid derivative (FCE 21589), which in 0-24-h urine samples of rat, monkey and man accounted for 30, 21 and 41% of urinary radioactivity, respectively. 6. Other metabolites identified in urine of all species resulted from hydrolysis of the urea moiety, the loss of the 3-dimethylaminopropyl group and the deallylation of the piperidine nitrogen.
摘要

相似文献

1
Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man.
Xenobiotica. 1993 Dec;23(12):1377-89. doi: 10.3109/00498259309059447.
2
Excretion balance and urinary metabolic pattern of [3H]cabergoline in man.人[3H]卡麦角林的排泄平衡及尿液代谢模式
Drug Metabol Drug Interact. 1992;10(3):199-211. doi: 10.1515/dmdi.1992.10.3.199.
3
The disposition and urinary metabolism of 14C-labelled FCE 22891, a pro-drug of FCE 22101, in animals.
J Antimicrob Chemother. 1990 Jan;25(1):133-9. doi: 10.1093/jac/25.1.133.
4
Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.新型认知增强剂NS-105的药代动力学。首次通讯:单次给予14C-NS-105后在大鼠、犬和猴体内的吸收、代谢及排泄情况
Arzneimittelforschung. 1999 Nov;49(11):881-90. doi: 10.1055/s-0031-1300521.
5
Disposition and biotransformation of quinpirole, a new D-2 dopamine agonist antihypertensive agent, in mice, rats, dogs, and monkeys.
Drug Metab Dispos. 1987 Jan-Feb;15(1):107-13.
6
Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man.14C-利福布汀在动物和人体内的吸收、分布及初步代谢途径
J Antimicrob Chemother. 1990 Dec;26(6):813-22. doi: 10.1093/jac/26.6.813.
7
On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man.多潘立酮在动物和人体中的药代动力学 Ⅲ. 多潘立酮在大鼠、犬和人体中的排泄与代谢的比较研究
Eur J Drug Metab Pharmacokinet. 1981;6(1):49-60. doi: 10.1007/BF03189515.
8
Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection.高效液相色谱-电化学检测法测定血浆和尿液中的卡麦角林
J Chromatogr. 1992 Feb 7;574(1):170-4. doi: 10.1016/0378-4347(92)80115-7.
9
Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.溴隐亭在动物和人体内的命运与处置。II:吸收、消除与代谢。
Eur J Drug Metab Pharmacokinet. 1983;8(1):51-62. doi: 10.1007/BF03189581.
10
Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.
Xenobiotica. 2004 Apr;34(4):379-89. doi: 10.1080/00498250410001670643.

引用本文的文献

1
Clinical pharmacokinetics of cabergoline.卡麦角林的临床药代动力学
Clin Pharmacokinet. 2003;42(7):633-45. doi: 10.2165/00003088-200342070-00003.
2
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.卡麦角林的药效学和药代动力学特征。用于帕金森病的理论依据。
Drugs. 1998;55 Suppl 1:10-6. doi: 10.2165/00003495-199855001-00002.
3
Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
卡麦角林。其药理学特性及治疗高催乳素血症和抑制泌乳的治疗潜力综述。
Drugs. 1995 Feb;49(2):255-79. doi: 10.2165/00003495-199549020-00009.